Your session is about to expire
← Back to Search
Doxycycline Hyclate Delayed-Release 200 mg for Chlamydia
Study Summary
This trial is testing whether taking an antibiotic called doxycycline immediately after sex can reduce the risk of STIs.
- Chlamydia
- Syphilis
- Gonorrhea
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are researchers currently looking for volunteers to join the trial?
"As per clinicaltrials.gov, this particular medical study is not enrolling patients at present time; the original posting date was November 26th 2019 and it was last revised on May 23rd 2022. However, there are 861 other research studies that currently require patient recruitment."
Has the FDA given assent to Doxycycline Hyclate Delayed-Release 200 mg?
"The safety of Doxycycline Hyclate Delayed-Release 200 mg is rated a 3 by Power, which reflects the approval status granted to this therapeutic agent after Phase 4 trials."
How many participants is this clinical trial accepting at the present time?
"At present, no further cohorts are being recruited for this investigation. The trial commenced on November 26th 2019 and concluded on May 23rd 2022. If you're looking to join other studies, 822 clinical trials related to gonorrhea are now inviting patients; 39 research projects that employ Doxycycline Hyclate Delayed-Release 200 mg as a treatment option currently have open recruitment slots."
In what medical scenarios is Doxycycline Hyclate Delayed-Release 200 mg typically prescribed?
"Doxycycline Hyclate Delayed-Release 200 mg is usually prescribed for severe acne, yet it can also play a part in managing conditions such as trachoma, disease and klebsiella infections."
Has Doxycycline Hyclate Delayed-Release 200 mg been trialed before in a medical setting?
"Doxycycline Hyclate Delayed-Release 200 mg was initially tested in 2010 at Uganda Ministry of Health: selected Arua and Nebbi district health centres. Since then, 159 such studies have been completed with 39 more currently underway - many of them based out of Seattle, Washington."
Share this study with friends
Copy Link
Messenger